Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash from Financing Activities (2019 - 2025)

Allogene Therapeutics' Cash from Financing Activities history spans 7 years, with the latest figure at $3.2 million for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 376.58% year-over-year to $3.2 million; the TTM value through Sep 2025 reached $28.0 million, down 74.76%, while the annual FY2024 figure was $116.7 million, 21.92% up from the prior year.
  • Cash from Financing Activities for Q3 2025 was $3.2 million at Allogene Therapeutics, down from $5.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $108.6 million in Q2 2024 and bottomed at $24000.0 in Q2 2022.
  • The 5-year median for Cash from Financing Activities is $2.4 million (2021), against an average of $13.1 million.
  • The largest annual shift saw Cash from Financing Activities plummeted 99.46% in 2021 before it surged 372916.67% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $322000.0 in 2021, then crashed by 85.71% to $46000.0 in 2022, then soared by 236.96% to $155000.0 in 2023, then surged by 3605.16% to $5.7 million in 2024, then crashed by 43.65% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Cash from Financing Activities are $3.2 million (Q3 2025), $5.1 million (Q2 2025), and $14.0 million (Q1 2025).